Literature DB >> 33531643

Interobserver variability in clinical target volume delineation in anal squamous cell carcinoma.

Kyung Su Kim1,2, Kwang-Ho Cheong3, Kyubo Kim4, Taeryool Koo3, Hyeon Kang Koh5, Ji Hyun Chang6, Ah Ram Chang7, Hae Jin Park8.   

Abstract

We evaluated the inter-physician variability in the target contouring of the radiotherapy for anal squamous cell carcinoma (ASCC). Clinical target volume (CTV) of three patients diagnosed with ASCC was delineated by seven experienced radiation oncologists from multi-institution. These patients were staged as pT1N1a, cT2N0, and cT4N1a, respectively, according to 8th edition of the American Joint Committee on Cancer staging system. Expert agreement was quantified using an expectation maximization algorithm for Simultaneous Truth and Performance Level Estimation (STAPLE). The maximum distance from the boundaries of the STAPLE generated volume with confidence level of 80% to those of the contour of each CTV in 6 directions was compared. CTV of pelvis which includes primary tumor, perirectal tissue and internal/external iliac lymph node (LN) area (CTV-pelvis) and CTV of inguinal area (CTV-inguinal) were obtained from the seven radiation oncologists. One radiation oncologist did not contain inguinal LN area in the treatment target volume of patient 2 (cT2N0 stage). CTV-inguinal displayed moderate agreement for each patient (overall kappa 0.58, 0.54 and 0.6, respectively), whereas CTV-pelvis showed substantial agreement (overall kappa 0.66, 0.68 and 0.64, respectively). Largest variation among each contour was shown in the inferior margin of the CTV-inguinal. For CTV-pelvis, anterior and superior margin showed the biggest variation. Overall, moderate to substantial agreement was shown for CTV delineation. However, large variations in the anterior and cranial boarder of the CTV-pelvis and the caudal margin of the CTV-inguinal suggest that further studies are needed to establish a clearer target volume delineation guideline.

Entities:  

Year:  2021        PMID: 33531643     DOI: 10.1038/s41598-021-82541-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  20 in total

1.  Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer.

Authors:  Michael Ng; Trevor Leong; Sarat Chander; Julie Chu; Andrew Kneebone; Susan Carroll; Kirsty Wiltshire; Samuel Ngan; Lisa Kachnic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-06       Impact factor: 7.038

2.  Image-guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer.

Authors:  Francesca Arcadipane; Pierfrancesco Franco; Manuela Ceccarelli; Gabriella Furfaro; Nadia Rondi; Elisabetta Trino; Stefania Martini; Giuseppe Carlo Iorio; Massimiliano Mistrangelo; Paola Cassoni; Patrizia Racca; Mario Morino; Umberto Ricardi
Journal:  Asia Pac J Clin Oncol       Date:  2017-08-30       Impact factor: 2.601

3.  Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Authors:  Leonard L Gunderson; Kathryn A Winter; Jaffer A Ajani; John E Pedersen; Jennifer Moughan; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544

4.  RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.

Authors:  Lisa A Kachnic; Kathryn Winter; Robert J Myerson; Michael D Goodyear; John Willins; Jacqueline Esthappan; Michael G Haddock; Marvin Rotman; Parag J Parikh; Howard Safran; Christopher G Willett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-12       Impact factor: 7.038

5.  Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas.

Authors:  Robert J Myerson; Michael C Garofalo; Issam El Naqa; Ross A Abrams; Aditya Apte; Walter R Bosch; Prajnan Das; Leonard L Gunderson; Theodore S Hong; J J John Kim; Christopher G Willett; Lisa A Kachnic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-29       Impact factor: 7.038

6.  Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.

Authors:  Robert Glynne-Jones; Per J Nilsson; Carlo Aschele; Vicky Goh; Didier Peiffert; Andrés Cervantes; Dirk Arnold
Journal:  Radiother Oncol       Date:  2014-06-16       Impact factor: 6.280

7.  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

Authors:  Roger D James; Robert Glynne-Jones; Helen M Meadows; David Cunningham; Arthur Sun Myint; Mark P Saunders; Timothy Maughan; Alec McDonald; Sharadah Essapen; Martin Leslie; Stephen Falk; Charles Wilson; Simon Gollins; Rubina Begum; Jonathan Ledermann; Latha Kadalayil; David Sebag-Montefiore
Journal:  Lancet Oncol       Date:  2013-04-09       Impact factor: 41.316

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  Bone Marrow-Sparing IMRT in Anal Cancer Patients Undergoing Concurrent Chemo-Radiation: Results of the First Phase of a Prospective Phase II Trial.

Authors:  Francesca Arcadipane; Patrick Silvetti; Francesco Olivero; Alessio Gastino; Viola De Luca; Massimiliano Mistrangelo; Paola Cassoni; Patrizia Racca; Elena Gallio; Adriana Lesca; Christian Fiandra; Umberto Ricardi; Pierfrancesco Franco
Journal:  Cancers (Basel)       Date:  2020-11-09       Impact factor: 6.639

10.  Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) - a prospective, randomized, 2-armed phase-II-trial.

Authors:  Nathalie Arians; Matthias Häfner; Johannes Krisam; Kristin Lang; Antje Wark; Stefan A Koerber; Adriane Hommertgen; Jürgen Debus
Journal:  BMC Cancer       Date:  2020-01-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.